Erratum to: Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma

Author： Morales La Madrid Andres   Campbell Nicholas   Smith Sonali   Cohn Susan   Salgia Ravi  

Publisher： Springer Publishing Company

ISSN： 1776-2596

Source： Targeted Oncology, Vol.8, Iss.4, 2013-12, pp. : 301-301

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 3, 2010-03 ,pp. : 236-249

Bentham Science Publishers

Access to resources Recommend Favorite

Pralatrexate: treatment of T-cell non-Hodgkin’s lymphoma

By Parker Terri   Barbarotta Lisa   Foss Francine  

Future Oncology, Vol. 9, Iss. 1, 2013-01 ,pp. : 21-29

Future Medicine

Access to resources Recommend Favorite

ALK inhibitors and advanced non-small cell lung cancer (Review)

By                  

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 499-508

Spandidos Publications

Access to resources Recommend Favorite

Impact of EGFR mutations on treatment of non-small cell lung cancer

By Johnson Bruce   Jackman David   Jänne Pasi  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 5-9

Springer Publishing Company

Access to resources Recommend Favorite

Impact of EGFR mutations on treatment of non-small cell lung cancer

By Johnson Bruce   Jackman David   Jänne Pasi  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 5-9

Springer Publishing Company

Access to resources Recommend Favorite